SYMDEKO (COPACKAGED) Drug Patent Profile

When do Symdeko (copackaged) patents expire, and what generic alternatives are available?

Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty-six patents protecting this drug.

This drug has four hundred and twenty-eight patent family members in forty-one countries.

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Symdeko (copackaged)

Symdeko (copackaged) was eligible for patent challenges on February 12, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 10, 2031. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMDEKO (COPACKAGED)

International Patents:	428
US Patents:	26
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMDEKO (COPACKAGED)
DailyMed Link:	SYMDEKO (COPACKAGED) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SYMDEKO (COPACKAGED)

Constraining patent/regulatory exclusivity:

RE50453

NDA:

210491

Dosage:

TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SYMDEKO (COPACKAGED)

SYMDEKO (COPACKAGED) is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent RE50453.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019		RX	Yes	No	7,495,103		Y	Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,354,427
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	8,410,274		Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	9,012,496
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	10,081,621		Y
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018		RX	Yes	Yes	7,776,905		Y	Y

Expired US Patents for SYMDEKO (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-002	Jun 21, 2019	8,629,162
Vertex Pharms Inc	SYMDEKO (COPACKAGED)	ivacaftor; ivacaftor, tezacaftor	TABLET;ORAL	210491-001	Feb 12, 2018	8,629,162

International Patents for SYMDEKO (COPACKAGED)

When does loss-of-exclusivity occur for SYMDEKO (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMDEKO (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007235260
Brazil	PI0710965
Canada	2648719
Canada	2869945
China	101460489
China	103254177

Supplementary Protection Certificates for SYMDEKO (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	C300748	Netherlands		PRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725
1773816	CA 2015 00038	Denmark		PRODUCT NAME: IVACAFTOR, N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF; REG. NO/DATE: EU/1/12/782/001-002 20120723
1773816	PA2015028	Lithuania		PRODUCT NAME: IVACAFTORUM; REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120723
1773816	C20150028 00162	Estonia		PRODUCT NAME: IVAKAFTOOR;REG NO/DATE: EU/1/12/782/001-002 25.07.2012
1773816	1590036-8	Sweden		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/12/782/001, 2012-07-25; DEN 2025-05-21 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590036-8,1690018-5, 1490016-1
1773816	15C0045	France		PRODUCT NAME: IVACAFTOR, OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725

SYMDEKO (copackaged) market dynamics and financial trajectory: pricing, volume, payer mix, exclusivity, and generic/biosimilar risk

Last updated: June 10, 2026

SYMDEKO (copackaged tezacaftor/ivacaftor; trade name marketed as a copackaged regimen) has a mature, brand-only CFTR-modulator lifecycle with declining growth drivers post-launch and increasing pressure from newer CFTR-modulator combinations. Financial trajectory in the near term is driven by (1) CF center prescribing patterns, (2) payer prior authorization and rebate structures, (3) competitive switching to next-generation triple/dual combinations where clinically appropriate, and (4) exclusivity and patent-end timing for tezacaftor and ivacaftor fixed-dose combinations.

How has the market performed for SYMDEKO (copackaged) in cystic fibrosis, and what drives demand?

Demand drivers

• Population addressed: SYMDEKO targets CF patients with eligible genotypes for tezacaftor/ivacaftor and is used under label-specific criteria that determine eligibility by genotype and age.
• Treatment setting: Use concentrates in CF specialty centers that manage longitudinal response monitoring and adherence.
• Therapy switching behavior: Prescribers shift when newer CFTR regimens provide better clinical outcomes, simpler dosing, or improved patient-reported outcomes within labeled eligibility.

Key market dynamics

• Payer control in high-cost specialty drugs: Utilization management (prior authorization, step edits, and outcomes-based criteria) tends to determine net pricing more than list price.
• Rebate negotiations: Brand-to-brand competition among CFTR modulators pushes manufacturers to defend formulary position via larger rebates and contracting concessions, which compresses net-to-gross.
• Geographic and formulary variability: Coverage changes can be faster in formularies where payers benchmark high-cost specialty classes and where competitive alternatives are already preferred.

Clinical practice effects

• Eligibility gating increases volatility: Any incremental changes to payer policies on genotype confirmation, age bands, or response measures can change volumes quickly.
• Adherence and copackaging: Copackaged regimens can be operationally more complex for patients and caregivers versus single-tablet regimens, which can affect persistence when payers or prescribers prefer simpler options.

What is SYMDEKO’s financial trajectory by revenue model, net pricing, and channel mix?

Revenue model (high level)

• Specialty pharmaceuticals like SYMDEKO typically monetize through:
  • Net price after rebates driven by competitive contracting.
  • Specialty pharmacy and buy-and-bill equivalents depending on country and payer ecosystem.
  • Volume retention tied to ongoing clinical use and persistence.

Net price pressure points

• Therapy class competition: When newer CFTR modulator regimens expand in formulary preferences, payers often reprice older modulators indirectly through contracting terms.
• Sequencing concessions: Manufacturers frequently match contracting benchmarks tied to outcomes and expected switching rates.

Financial trajectory pattern seen in mature specialty CF brands

• Early-to-mid lifecycle: Strong uptake and high net pricing during initial penetration among eligible patients.
• Later lifecycle: Growth slows as eligible patient pools saturate and as competition drives churn risk.
• Late lifecycle: Revenue stabilizes or declines modestly unless contract renewals preserve coverage or label expansions extend the addressable population.

How do payer negotiations and rebate pressure affect SYMDEKO’s net revenue?

Mechanisms that compress net

• Formulary placement drives rebate size: When payers place competing CFTR modulators as preferred, they demand larger rebates for non-preferred agents.
• Clinical criteria in outcomes terms: Payers increasingly tie coverage to genotype documentation and clinical monitoring requirements.
• Contracting leverage: Larger integrated payer groups negotiate class-level pricing due to high budget impact in CF modulator categories.

What changes quickly

• PA criteria: Tightening PA criteria can reduce new starts even if existing patients remain covered.
• Switch incentives: Contracts can include incentives or administrative requirements that promote switching at refill or at clinical re-evaluation intervals.

When does SYMDEKO (copackaged) lose exclusivity, and what does that imply for revenue?

Exclusivity and generic entry risk

• For branded specialty drugs with fixed-dose CFTR modulator regimens, revenue risk concentrates around:
  • Patent expiry of composition-of-matter and fixed-dose combination claims
  • Patent expiry of formulation and dosing regimen claims
  • Orphan/other exclusivity, if applicable, and whether it delays generic approval
  • Market entry timing after launch of approved generics and label carve-outs

Implication for financial trajectory

• Pre-expiry: Revenue typically remains stable but growth slows as biosimilar/generic entrants are not yet clinically or contractually viable.
• Post-expiry with Paragraph IV: Revenue can decline rapidly once a generic launches and formulary access is reconfigured.
• Post-expiry without immediate launch: Revenue can stay elevated longer if generic manufacturers cannot clear patent barriers or if litigation delays approval.

What patents protect SYMDEKO (tezacaftor/ivacaftor) and how strong is the estate against generic challenges?

Patent estate pressure points

• Combination claims: Fixed-dose copackaged products are often attacked through combination and method-of-treatment claims that cover eligible genotypes and dosing schedules.
• Formulation and dosing patents: Copackaging and tablet strengths are frequently protected by formulation and stability claims.
• Method-of-use claims: CFTR modulator regimens may include methods for treating eligible CF genotypes, which can add legal friction for generics aiming to maintain the same clinical positioning.

Business impact

• A strong estate delays generic substitution and supports higher net pricing due to maintained formulary exclusivity.
• A fragmented or expiring estate can lead to quicker erosion via authorized generics or full generic entry, depending on litigation outcomes.

Are there Paragraph IV ANDA challenges or generic launch risks for SYMDEKO?

Generic entry dynamics

• For CFTR modulators, generic entry risk tends to be shaped by:
  • Whether the FDA can approve an ANDA while respecting granted patents
  • Whether challengers use carve-outs to avoid infringing labeling
  • Whether courts enter injunctions or narrow claims

Financial trajectory effect

• ANDA with successful infringement outcomes: Net revenue declines as payers switch to lower-cost alternatives.
• Paragraph IV loss or settlements: Revenue decline is slower and may be delayed until later in the patent timeline.

How does SYMDEKO compare with newer CFTR modulators in switching risk and revenue exposure?

Competitive landscape

• The CFTR modulator market has progressed from dual regimens toward combination approaches that can consolidate efficacy and simplify dosing for some patients.
• Revenue exposure for SYMDEKO is tied to:
  • Clinically eligible overlap between SYMDEKO and newer regimens
  • Payer preference evolution as formularies migrate to lower-cost contracted options
  • Prescriber inertia balanced against clinical response and convenience

Switching risk framework (practical)

• Highest risk: patients newly starting therapy and those with less stable response who can be moved at re-evaluation.
• Lower risk: stable patients when payers and centers apply “stay-on-therapy” policies pending clinical change.

What is the Orange Book status of SYMDEKO (copackaged), and how many listed patents matter?

Orange Book-driven questions

• The Orange Book lists patents tied to:
  • Active ingredient and approved drug product
  • Formulation and method-of-use
• For financial forecasting, the number and type of listed patents shape:
  • Likelihood of generic launch around expiry
  • Timing of eligibility for Paragraph IV certifications

Materiality

• Not all listed patents are equally enforceable against a given generic product. Composition, fixed-dose combination, and method-of-use patents typically matter most for infringement.

What FDA milestones and label coverage determine SYMDEKO’s commercial trajectory?

Commercial levers

• Label expansions can increase addressable patient pools and stabilize revenues.
• Safety updates and restrictions can slow use if additional monitoring or criteria restrict eligibility.
• Real-world uptake often lags label expansions due to payer and center protocols.

Net effect on trajectory

• Label expansions tend to extend plateau length.
• Additional restrictions can accelerate decline by reducing eligible starts.

What litigation, settlements, and regulatory events could change SYMDEKO revenue quickly?

Litigation pathways

• Patent infringement suits can delay or shape generic approval.
• Section viii settlements (where applicable) can set “at-risk” launch schedules and define timing for exclusivity carve-outs.

Regulatory events

• Changes in FDA labeling or REMS requirements can materially alter prescribing and payer coverage workflows.

Market impact timing

• Revenue effects generally appear in two windows:
  • Before launch: proactive contracting shifts can reduce future volume.
  • At launch: sudden net price drop and forced formulary substitution accelerates revenue erosion.

How much revenue exposure does SYMDEKO have under different generic entry scenarios?

Scenario map

• No generic entry at expiry: Revenue declines slowly via class competition and incremental patient switching.
• Generic entry with full-label substitution: Rapid erosion is likely due to payer-driven switching and rebasing of contracts.
• Generic entry with label carve-outs: Commercial impact depends on how much overlap exists with covered populations; revenue erosion is typically partial.

Operational reality

• For specialty drugs, net revenue loss can outpace volume declines because rebates and contract terms often deteriorate even in the absence of immediate switching.

Key financial indicators to watch for SYMDEKO (copackaged) going forward

Contract and coverage

• Preferred vs non-preferred formulary status across major PBMs
• PA criteria for genotype eligibility and monitoring frequency
• Rebate rate changes in CFTR modulator contracts

Utilization

• New starts trend vs persistence trend
• Switch-out rate to competing CFTR regimens
• Specialty pharmacy inventory behavior and pull-through

Regulatory and IP

• Patent expiry milestones and Orange Book changes
• Litigation docket updates affecting launch timing
• FDA approval events for generic/same-class competitors

Key Takeaways

• SYMDEKO’s financial trajectory is dominated by net pricing compression from CFTR modulator competition and by switching dynamics to newer combination regimens within labeled eligibility.
• The highest financial risk window for SYMDEKO centers on patent expiry and any successful Paragraph IV pathway that enables generic entry with meaningful label coverage.
• Payer behavior, not clinical performance alone, drives quarterly revenue changes through formulary preference, PA criteria, rebate size, and administrative switching protocols.
• Revenue outlook is most sensitive to (1) exclusivity/patent-end timing for tezacaftor/ivacaftor fixed-dose copackaging and (2) whether generic challengers can launch without label carve-outs or injunction-related delays.

FAQs

1. How quickly do payers switch patients from older CFTR modulators to newer regimens after formulary changes?
2. What typically happens to net revenue for a mature specialty CF drug when a preferred competitor enters a major PBM formulary?
3. Do authorized generics or settlement-based “launch at risk” dates usually change revenue sooner than patent expiry itself?
4. How do label carve-outs in generic approvals affect retained market share for the reference brand?
5. What is the commercial impact of copackaging logistics on adherence and persistence compared with single-tablet regimens?

References (APA)

1. (No sources provided.)